Search
                    Head and Neck Cancer Paid Clinical Trials in Wisconsin
A listing of 10  Head and Neck Cancer  clinical trials  in Wisconsin  actively recruiting volunteers for paid trials and research studies in various therapeutic areas.
            1 - 10 of 10
        
        
    
                The state of Wisconsin currently has 10 active clinical trials seeking participants for Head and Neck Cancer research studies. These trials are conducted in various cities, including Milwaukee, Madison, Green Bay and Marshfield. 
            
                                Featured Trial
                
                Healthy Participants Needed (Colonoscopy + Cancer Screening)
            
        Recruiting
            
        Earn $325 - $475 in electronic payment card compensation for your time and effort by participating in a clinical study to develop a blood test that may one day help screen for colon cancer. Take a quick quiz to see if you qualify.
    
    
                            Conditions: 
                                    
        
            
                        Healthy
                    
                                    
                        Healthy Volunteers
                    
                                    
                        Healthy Subjects
                    
                                    
                        Healthy Volunteer
                    
                                    
                        Healthy Participants
                    
                                    Featured Offer
                
                Lose Weight with GLP-1 Medications
            
        Recruiting
            
        Policy Lab has partnered with OnlineSemaglutide.org to offer trusted access to semaglutide and other GLP-1 medications, including generic alternatives to Ozempic® and Wegovy®. 
GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
    GLP-1 medications are scientifically backed to help individuals achieve significant weight loss—on average, 15-20% of body weight within a year.
As a valued user, you’re eligible for $50 off your first program with code policy-lab-50.
                            Conditions: 
                                    
        
            
                        Overweight
                    
                                    
                        Overweight and Obesity
                    
                                    
                        Obesity
                    
                                    
                        Weight Loss
                    
                                    
                        Morbid Obesity
                    
                                    Featured Trial
                
                Stroke Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Stroke
    
    
                            Conditions: 
                                    
        
            
                        Stroke
                    
                                    Featured Trial
                
                Chronic Kidney Disease (CKD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Chronic Kidney Disease (CKD)
    
    
                            Conditions: 
                                    
        
            
                        Chronic Kidney Disease (CKD)
                    
                                    Featured Trial
                
                Ischemic heart disease (IHD) Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Ischemic heart disease (IHD)
    
    
                            Conditions: 
                                    
        
            
                        Ischemic heart disease (IHD)
                    
                                    Featured Trial
                
                Cardiovascular Disease Clinical Study
            
        Recruiting
            
        A clinical study for people that suffer with Cardiovascular Disease
    
    
                            Conditions: 
                                    
        
            
                        Cardiovascular Disease
                    
                                    
                
                                    The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE)
                                
            
            
        Recruiting
                            
            
                The Phase 2 monotherapy portion of this study is currently enrolling and will evaluate the efficacy and safety of PC14586 (INN rezatapopt) in participants with locally advanced or metastatic solid tumors harboring a TP53 Y220C mutation. The Phase 1 portion of the study will assess the safety, tolerability and preliminary efficacy of multiple dose levels of rezatapopt as monotherapy and in Phase 1b in combination with pembrolizumab.             
        
        
    Gender:
                ALL
            Ages:
                12 years and above
            Trial Updated:
                08/04/2025
            
            Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin         
        
        
            Conditions: Advanced Solid Tumor, Advanced Malignant Neoplasm, Metastatic Cancer, Metastatic Solid Tumor, Lung Cancer, Ovarian Cancer, Endometrial Cancer, Prostate Cancer, Colorectal Cancer, Breast Cancer, Other Cancer, Locally Advanced, Head and Neck Cancer, Gall Bladder Cancer, Small Cell Lung Cancer, Small Cell Lung Cancer ( SCLC ), Small Cell Lung Carcinoma, NSCLC, NSCLC (non-small Cell Lung Cancer), SCLC, Non-Small Cell Lung Carcinoma, Triple Negative Breast Cancer, TNBC, HER2+ Breast Cancer, Non-Small Cell Lung Cancer, ER/PR Positive Breast Cancer, HER2- Breast Cancer, HER2-positive Breast Cancer, HER2-negative Breast Cancer, ER/PR(+), Her2(-) Breast Cancer
        
            
        
    
                
                                    Postoperative Radiotherapy for Intermediate- and High-risk Patients With HNSCC Greater Than 6 Weeks After Surgery
                                
            
            
        Recruiting
                            
            
                The goal of this clinical trial is to determine whether accelerated radiotherapy (involving 6 treatments per week) is better than standard radiotherapy (involving 5 treatments per week) at treating cancer of the head and neck when initiated more than 6 weeks after surgery.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/16/2025
            
            Locations: Advocate Aurora Radiation Oncology, Milwaukee, Wisconsin         
        
        
            Conditions: Head and Neck Cancer, Head and Neck Squamous Cell Carcinoma HNSCC
        
            
        
    
                
                                    Pilot Study of Imatinib Cetuximab Combo for H & N Cancer
                                
            
            
        Recruiting
                            
            
                The goal of this clinical trial is to find if levels of a protein called AXL in tumor cells relate to how tumors respond to cetuximab (CTX) combined with imatinib in participants with head and neck cancer. This interventional study will occur in the time between diagnosis of your cancer and surgery to remove your tumor or radiation or chemoradiation treatment of your primary cancer.
Participants will undergo a research blood draw and a research biopsy as part of the screening process, and will...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/14/2025
            
            Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin         
        
        
            Conditions: Head and Neck Cancer, Squamous Cell Carcinoma of Head and Neck
        
            
        
    
                
                                    Mental Health App for Cancer Survivors Study
                                
            
            
        Recruiting
                            
            
                The goal of this clinical trial is to adapt a mental health digital app to treat depression among head and neck cancer patients and survivors.
Participants will download and use the digital mental health app for a 6-week period, and will complete related surveys.             
        
        
    Gender:
                ALL
            Ages:
                22 years and above
            Trial Updated:
                05/29/2025
            
            Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin         
        
        
            
        
    
                
                                    Study Transplanting Bone Marrow Cells Into Salivary Glands to Treat Dry Mouth Caused by Radiation Therapy
                                
            
            
        Recruiting
                            
            
                The goal of this clinical research study is to evaluate the safety and tolerability of injecting certain cells that you produce in your bone marrow called mesenchymal stem cells (MSCs) into your salivary glands.
Participants will have head and neck cancer that was treated with radiation therapy, and in this study will:
* Undergo a collection of bone marrow using a needle;
* Donate saliva;
* Undergo a salivary gland ultrasound; and,
* Complete questionnaires that ask about dry mouth
Participan...  Read More             
        
        
    Gender:
                ALL
            Ages:
                Between 18 years and 90 years
            Trial Updated:
                05/06/2025
            
            Locations: University of Wisconsin Carbone Cancer Center, Madison, Wisconsin         
        
        
            Conditions: Head and Neck Cancer, Xerostomia
        
            
        
    
                
                                    A Study of PARG Inhibitor IDE161 in Participants With Advanced Solid Tumors
                                
            
            
        Recruiting
                            
            
                The purpose of this study is to characterize the safety, tolerability, and efficacy of IDE161 as a single agent and in combination with pembrolizumab.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                03/31/2025
            
            Locations: University of Wisconsin, Madison, Wisconsin         
        
        
            Conditions: Advanced or Metastatic Solid Tumors, Breast Cancer, Ovarian Cancer, Prostate Cancer, Endometrial Cancer, Colorectal Cancer, Head and Neck Cancers, Nsclc
        
            
        
    
                
                                    Hypofractionated Preoperative Radiation for Head and Neck Cancers (HyPR-HN)
                                
            
            
        Recruiting
                            
            
                This is a phase 1 study to determine the safety of a condensed preoperative radiation regimen (10, 7, or 5 fractions) for the management of head and neck squamous cell carcinoma.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                02/24/2025
            
            Locations: Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin         
        
        
            Conditions: Head and Neck Cancer
        
            
        
    
                
                                    Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression
                                
            
            
        Recruiting
                            
            
                This clinical trial is evaluating a drug called BT5528 alone and in combination with nivolumab in participants with advanced solid tumors historically known for expression of EphA2. The main goals of this study are to:
* Find the recommended dose(s) of BT5528 that can be given safely to participants alone and in combination with nivolumab
* Learn more about the side effects of BT5528
* Learn about how effective BT5528 is for the treatment of ovarian cancer, urothelial/bladder cancer, lung cance...  Read More             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                11/20/2024
            
            Locations: Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin         
        
        
            Conditions: Advanced Solid Tumor Historically Known for High EphA2 Expression, Urothelial Cancer, Ovarian Cancer, Non-small Cell Lung Cancer, Head and Neck Cancer, Triple Negative Breast Cancer, Gastric/Upper Gastrointestinal Cancer
        
            
        
    
                
                                    Study of INBRX-106 and INBRX-106 in Combination With Pembrolizumab (Keytruda®) in Subjects With Locally Advanced or Metastatic Solid Tumors (Hexavalent OX40 Agonist)
                                
            
            
        Recruiting
                            
            
                This is a Phase 1/2, open-label, non-randomized, 4-part trial to determine the safety profile and identify the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of INBRX 106 administered as a single agent or in combination with the anti-PD-1 checkpoint inhibitor (CPI) pembrolizumab (Keytruda®). KEYTRUDA is a registered trademark of Merck Sharp \& Dohme LLC, a subsidiary of Merck \& Co., Inc., Rahway, NJ, USA.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                07/17/2024
            
            Locations: Froedtert Hospital and the Medical College of Wisconsin, Milwaukee, Wisconsin         
        
        
            Conditions: Solid Tumor, Non-Small Cell Lung Cancer, Melanoma, Head and Neck Cancer, Gastric Cancer, Renal Cell Carcinoma, Urothelial Carcinoma
        
            
        
    
                
                                    The MOMENTUM Study: The Multiple Outcome Evaluation of Radiation Therapy Using the MR-Linac Study
                                
            
            
        Recruiting
                            
            
                The Multi-OutcoMe EvaluatioN of radiation Therapy Using the Unity MR-Linac Study (MOMENTUM) is a multi-institutional, international registry facilitating evidenced based implementation of the Unity MR-Linac technology and further technical development of the MR-Linac system with the ultimate purpose to improve patients' survival, local, and regional tumor control and quality of life.             
        
        
    Gender:
                ALL
            Ages:
                18 years and above
            Trial Updated:
                09/25/2023
            
            Locations: Medical College of Wisconsin, Milwaukee, Wisconsin         
        
        
            Conditions: Oncology, Breast Cancer, Prostate Cancer, Gynecologic Cancer, Brain Tumor, Brain Cancer, Gynecologic Tumor, Prostate Tumor, Prostate Neoplasm, Breast Tumor, Radiation Toxicity, Quality of Life, Rectal Cancer, Rectal Tumor, Rectal Neoplasms, Lung Cancer, Lung Tumor, Lung Neoplasm, Esophageal Cancer, Esophagus Cancer, Esophageal Tumor, Esophageal Neoplasm, Esophagus Tumor, Esophagus Neoplasm, Pancreatic Cancer, Pancreatic Tumor, Pancreatic Neoplasms, Head and Neck Cancer, Head and Neck Neoplasms, Head and Neck Tumor, Tumor, Neoplasms, Bladder Cancer, Bladder Neoplasm, Liver Cancer, Liver Neoplasms, Liver Metastases, Oligometastases
        
            
        
    1 - 10 of 10
            
            
        